Prohemostatic proteins for the treatment of bleeding
AssigneeAcademisch Ziekenhuis Leiden
InventorsDaniël Verhoef, Pieter H. Reitsma, Mettine H. A. Bos
Life of this patent
Estimating the term…
Abstract
This disclosure relates to recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.
Claims19
A recombinant protein comprising a coagulation factor Xa polypeptide, said coagulation factor Xa polypeptide having an alteration in a region of amino acid residues corresponding to the region of amino acid residues between Gly-289 and Asp-320 of SEQ ID NO:
- 1, wherein the alteration is an insertion of at least one amino acid residue.
(canceled)
(canceled)
Dependencies are inferred from the claim text.